Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.

The solubility of camptothecin (CPT), a highly potent antineoplastic agent, as a function of different concentrations of cyclodextrins (alpha-cyclodextrin, alpha-CD; beta-cyclodextrin, beta-CD; and gamma-cyclodextrin, gamma-CD; hydroxypropyl-beta-cyclodextrin, HP-beta-CD; and randomly substituted dimethyl-beta-cyclodextrin, RDM-beta-CD, and dimethyl-gamma-cyclodextrin, RDM-beta-CD) in 0.02 N HCl solution at 25 degrees C was investigated. The results showed a linear increase in the solubility of CPT with increasing concentration of CDs. The apparent stability constants (K(c)) for the CPT complexes with alpha-CD, beta-CD, gamma-CD, HP-beta-CD, RDM-beta-CD, and RDM-gamma-CD were 188, 266, 73, 160, 910, and 40.6 M(-1), respectively, suggesting that RDM-beta-CD afforded the most stable complex. At a 25% w/v concentration of RDM-beta-CD, the solubility of CPT was 228.45 +/- 8.45 microg/ml, about 171 times higher than that in 0.02 N HCl. The stability of CPT in pH 7.4 buffer at 25 degrees C also increased linearly with an increase in the concentration of RDM-beta-CD. The observed pseudo-first-order hydrolysis rate constants (k(obs)) for the free and complexed CPT were 11.8 x 10(-3) and 1.18 x 10(-3) min(-1), corresponding to an increase in half-life of CPT from 58.7 to 587.3 min, respectively. The preliminary cytotoxicity study against the human-derived myeloid THP-1 leukemia cell line showed RDM-beta-CD/CPT and HP-beta-CD/CPT complexes to be about two-fold more active than free CPT. In conclusion, the results showed that CDs, in general, and RDM-beta-CD, in particular, are effective complexing agents and can be used to improve the solubility and stability of CPT. The increase in cytotoxicity of CPT in the presence of CD is likely due to an increase in its stability.

[1]  B. Giovanella,et al.  Antitumor effect of liposome‐incorporated camptothecin in human malignant xenografts , 1995, Anti-cancer drugs.

[2]  D O Thompson,et al.  Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals. , 1997, Critical reviews in therapeutic drug carrier systems.

[3]  Leroy F. Liu.  DNA Topoisomerases : Topoisomerase-targeting drugs , 1994 .

[4]  R. Perez-soler,et al.  Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies , 1996, Cancer Chemotherapy and Pharmacology.

[5]  R J Reitemeier,et al.  Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. , 1972, Cancer chemotherapy reports.

[6]  M. Manfait,et al.  Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. , 1998, Biochimica et biophysica acta.

[7]  N. Bodor,et al.  The effects of 2-hydroxypropyl-β-cyclodextrin on the solubility and stability of chlorambucil and melphalan in aqueous solution , 1989 .

[8]  P. Pantazis,et al.  The camptothecins : from discovery to the patient , 1996 .

[9]  E. Eisenhauer,et al.  Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.

[10]  V. Stella,et al.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. , 1992, Journal of pharmaceutical sciences.

[11]  V. Stella,et al.  Comparative Effects of (SBE)7m‐β‐CD and HP‐β‐CD on the Stability of Two Anti‐neoplastic Agents, Melphalan and Carmustine , 2000 .

[12]  L. Szente,et al.  Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. , 1999, Advanced drug delivery reviews.

[13]  Gottlieb Ja,et al.  Treatment of malignant melanoma with camptothecin (NSC-100880). , 1972 .

[14]  B. Lundberg.  Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions. , 1998, Anti-cancer drug design.

[15]  D. Bindra,et al.  Plasma Pharmacokinetics of the Lactone and Carboxylate Forms of 20(S)-Camptothecin in Anesthetized Rats , 1993, Pharmaceutical Research.

[16]  J. Beijnen,et al.  Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. , 1990, Journal of pharmaceutical and biomedical analysis.

[17]  C. Nastruzzi,et al.  Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion , 1997 .

[18]  E K Rowinsky,et al.  The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.

[19]  D. Burk,et al.  The Determination of Enzyme Dissociation Constants , 1934 .

[20]  C. Conover,et al.  Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. , 1996, Journal of medicinal chemistry.

[21]  T. Burke,et al.  Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[22]  S. Balasubramanian,et al.  Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. , 1995, Journal of pharmaceutical sciences.

[23]  T. Higuchi,et al.  Investigation of some complexes formed in solution by caffeine. IV. Interactions between caffeine and sulfathiazole, sulfadiazine, p-aminobenzoic acid, benzocaine, phenobarbital, and barbital. , 2006, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[24]  R. Larson,et al.  Mevalonic acid induces DNA synthesis in chronic lymphocytic leukemia cells. , 1984, Blood.

[25]  H. Pinedo,et al.  Camptothecins New Anticancer Agents , 1994 .

[26]  T. Burke,et al.  Liposomal stabilization of camptothecin's lactone ring , 1992 .

[27]  H. Burt,et al.  Solubility and stability of taxol: effects of buffers and cyclodextrins , 1996 .

[28]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[29]  M. Wirth,et al.  Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. , 1999, Journal of controlled release : official journal of the Controlled Release Society.